

Revance irons out the wrinkles with its longer-acting Botox



Amy Brown

Botox's almost complete domination of the neuromuscular blocking agent market has held off a couple of rivals; however, its new owner, Abbvie, might soon face a bigger challenge. Revance Therapeutics' daxibotulinumtoxinA has been designed to be longer acting, and the first pivotal results in a medical setting seem to confirm this. The [Aspen 1](#) trial in cervical dystonia found a median duration of response of 20-24 weeks; according to a cross-trial comparison put together by Revance, Botox wears off around six weeks sooner. This was a secondary measure of Aspen, which pitted two doses of daxi against placebo; the primary endpoint, change on a symptom score, [was cleared with statistical significance](#). The inclusion of a Botox cohort would have made these findings more interesting, of course, although Revance's reluctance to go head to head is understandable. The real battle will take place in the market, and Revance would not have wanted to risk handing an unwanted finding to Abbvie's sales team. Revance needs to build a picture of a long-acting and safer option, and [several trials](#) due to report next year could help. The next hurdle is [FDA approval](#), due next month in glabellar lines.

This story has been corrected to clarify that daxi duration of response was measured in weeks.

Duration of Effect for DaxibotulinumtoxinA for Injection, BOTOX® and Myobloc®




Figure 2, from Comella 2005
All subjects had previous successful treatment with BoNTA, with a subjective report of at least 30% benefit.


Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons.
¹Comella C. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005.



Source: Revance presentation.

Outlook for daxibotulinumtoxinA

sellside consensus



EvaluatePharma

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2022 Evaluate Ltd.